株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

NASH薬剤市場:2015〜2025年

NASH Drugs Market, 2015 - 2025

発行 ROOTS ANALYSIS 商品コード 339746
出版日 ページ情報 英文 188 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: ROOTS ANALYSIS社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
NASH薬剤市場:2015〜2025年 NASH Drugs Market, 2015 - 2025
出版日: 2015年09月03日 ページ情報: 英文 188 Pages
概要

NASH (非アルコール性脂肪性肝炎) は未だ原因がわかっておらず、米国では肝臓移植につながる第3位の要因となっています。南北アメリカのおよそ2〜5%が罹患していると予測されており、次なるC型肝炎といわれています。

当レポートでは、NASH薬剤市場の現状と将来的見通しについて調査し、2025年までの市場予測、参入企業のプロファイル、および機会分析などをまとめています。

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 概要と背景
  • NASHの概念
  • 標的とする患者人口
  • NASHの病因
  • 疫学
  • 動物モデル
  • 治験デザインとエンドポイント
  • 法規制イニシアティブ

第4章 治療方法と診断方法

  • 概要と背景
  • 治療方法
  • 診断方法

第5章 市場動向

  • 本章の概要
  • 主な成長促進因子
    • 肥満と糖尿病の世界的罹患率の上昇
    • 研究開発イニシアティブの増加
    • 後期有望分子
  • 課題
    • NASHの病態生理学の理解不足
    • NASHの診断ツールの不完全性

第6章 市場概要

  • 概要と背景
  • 薬剤パイプライン
  • パイプライン分析
    • 開発段階別
    • 分子別
    • 投与ルート別

第7章 詳細プロファイル

第8章 市場規模と機会分析

  • 本章の概要
  • 重要パラメーターと予測
  • シナリオ分析
  • 市場全体の動向:2015〜2025年

第9章 企業プロファイル

  • 本章の概要
  • Conatus Pharmaceuticals
  • Galmed Pharmaceuticals
  • Genfit
  • Gilead Sciences
  • Intercept Pharmaceuticals
  • Novo Nordisk
  • Raptor Pharmaceuticals
  • Zydus Cadila

第10章 結論

第11章 インタビュー原稿

第12章 付録1:データ表

第13章 付録2:企業・組織リスト

図表

目次
Product Code: RA10046

NASH or Non-Alcoholic Steatohepatitis refers to a chronic liver disorder characterized by accretion of fat (lipid droplets), along with inflammation and degeneration of hepatocytes. In other words, it can be defined as significant steatohepatitis not caused due to alcohol, drugs, toxins, infectious agents or other identifiable exogenous causes. NASH is often accompanied with a high possibility of cirrhosis, a condition in which the liver functions are changed, leading to liver insufficiency. Although NASH has become quite common, there is still no clarity about the underlying cause of the disease. It is currently the third most common factor leading to liver transplants in the US. Estimated to affect around 2-5% of Americans, NASH has been cited as the next hepatitis C.

Given the rising prevalence of NASH, it has become all the more crucial to understand the pathophysiology of NASH in order to develop therapeutic interventions. Several options are being investigated to identify an efficient treatment regimen for NASH; these include lifestyle modifications, off-label therapies, natural products and combinations of these approaches. However, the diagnostic landscape for NASH is quite challenging; majority of the patients are asymptomatic and can only be detected by routine blood tests showing elevations in liver enzymes. At present, liver biopsy is being used as the only reliable way to diagnose NASH and detect the presence of fibrosis; however, very few patients choose to undergo liver biopsy because of its invasive nature.

Recognizing the huge unmet medical need, several companies are striving to establish an early foothold in the area. Investigators are also looking forward to exploiting the approach of personalized medicine in order to identify diagnostic biomarkers, prognostic biomarkers and therapeutic targets for the treatment of NASH on the basis of their pathogenic and clinical traits.

Synopsis:

The ‘NASH Drugs Market, 2015-2025' report provides a comprehensive study on the current landscape and the future outlook of the evolving pipeline of molecules in this area. With an expanding NAFLD and NASH population worldwide, there is a growing need for development of therapeutics in this disease area. NASH is gradually emerging as the leading cause of liver transplants. While the field has garnered interest of several companies, there are no approved therapies till date. It is important to stress that the development pipeline of NASH has several promising candidates that are likely to result in many commercial success stories in the foreseen future.

Amongst other elements, the report elaborates on the new diagnostic solutions being developed and the upcoming opportunities for different stakeholders. As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report is to understand the future potential of the market. This is done by analyzing:

  • The epidemiology, patient population and staging of NASH in different geographies.
  • The NASH pipeline in terms of phase of development, type of molecule, route of administration and mechanism of action.
  • The likely evolution in the rate of diagnosis, drug treated patient population and the likely price of the drugs.
  • The associated constraints, in terms of undefined pathogenesis and the unavailability of non-invasive diagnostic tests, and the initiatives being carried out by the companies to overcome these.

The study provides a detailed scenario analysis to estimate the market forecast for the period till 2025. The research, analysis and insights presented in this report include potential sales of the drugs in late stages of development and expected to launch by 2025. Our opinions and insights, presented in this study, were influenced by the discussions that we conducted with experts in this area. These included senior representatives at BiOrion Technologies, Phenex Pharmaceuticals, Tobira Therapeutics, Verlyx Pharmaceuticals and Connexios.

All actual figures have been sourced and analyzed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. During the course of our study, we identified over 50 molecules. Of these, two molecules (Lipaglyn by Zydus Cadila and OCA by Intercept Pharmaceuticals) are in phase 3 clinical studies. Nearly 37% of the pipeline is captured by molecules in phase 2 and 22% in phase 1. Additionally, 35% of the molecules are in preclinical / discovery phase, demonstrating the strong market potential of this field.
  • 2. Amongst several companies expanding in this domain, Intercept Pharmaceuticals is expected to launch INT 747 in the US and EU5 countries in 2017/2018. Subsequently, Genfit (GFT505), Gilead Sciences (GS-6624), Conatus Pharmaceuticals (Emricasan), Galmed Pharmaceuticals (Aramchol) and Raptor Pharmaceuticals (RP103) are expected to complete the clinical trials of their respective molecules in the coming years, sustaining the growth momentum.
  • 3. Lack of competent diagnostic tests has led to a poor diagnosis rate and management of NASH so far. Liver biopsy is currently the gold standard to validate the presence of NASH. We believe that merely 5% - 10% of the total patients suffering from the disease are actually being diagnosed in the US and the EU 5 countries. In addition to developments of tests to diagnose NASH, many small and mid-sized firms are now developing companion diagnostics alongside their NASH drug candidates.
  • 4. The market is fragmented with several start-ups actively involved in this area. Examples (in alphabetical order) include Cerenis Therapeutics, DS Biopharma, Galectin Therapeutics, Immuron, Islet Sciences, Matinas BioPharma, Metabolic Solutions, Naia Pharmaceuticals, Nimbus Therapeutics, Verva Pharmaceuticals, ViroBay and Zafgen.
  • 5. The overall market is likely to be influenced by several parameters such as diagnosis rate, drug penetration and the likely price of the drugs. We expect the market to witness an aggressive growth rate of close to 90%, emerging as a multi-billion dollar market by 2025. However, with successful reimbursement practices and launch in wider markets, the overall opportunity could be much higher.

Research Methodology:

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the market for NASH drugs is headed in the mid to long term.

Chapter 3 provides a general introduction to NASH, underlying the basic concepts of this disease area. In this section, we have briefly discussed the causes, classification, symptoms and different stages of NASH. Additionally, we have highlighted the historical evolution, pathogenesis, prevalence and the target patient population of NASH.

Chapter 4 gives an overview of the treatment and diagnostic solutions associated with NASH. We have discussed, in detail, the general recommendations, pharmacological interventions and natural remedies for treatment of the disease. This chapter also covers the non-invasive means of evaluating and staging NAFLD patients.

Chapter 5 summarises the market dynamics of NASH. It highlights the key drivers and restraints likely to influence the evolution of this market. In addition, it also covers the various research and development initiatives which have been takenby different stakeholders in this domain.

Chapter 6 provides a comprehensive market overview highlighting the therapeutics being developed to treat NASH. It offers an elaborate analysis of the drugs under development with their phase of development, route of administration, type of molecule and the mechanism of action.

Chapter 7 presents detailed profiles of the drugs in advanced stages of development.Each profile provides the drug overview, background, mechanism of action, current development status, key clinical trials, respective results andother recent developments associated with the drug.

Chapter 8 offersa scenario based approach to determine the overall market opportunity for NASH drug developers in the coming decade. The analysis highlights the likely evolution of important parameters such as the diagnosis rate, drug penetration rates and annual pricing. In addition, we have also presented an indicative distribution of the overall market amongst the different drugs likely to be launched in the near future..

Chapter 9 provides detailed company profiles of the leading players in the market. Each company profile includes information such as financial performance, product portfolio, recent collaborations and future outlook.

Chapter 10 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 11 is a collection of interview transcripts of the discussions which were held during the course of this study. For the purposes of this study, we held discussions with seniormost representatives at BiOrion Technologies, Phenex Pharmaceuticals, Tobira Therapeutics, Verlyx Pharmaceuticals and Connexios.

Chapter 12 is an appendix which provides tabulated data and numbers for all the figures provided in the report.

Chapter13 is an appendix which provides the list of companies mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. The Concept of NASH
  • 3.3. Target Patient Population
  • 3.4. Pathogenesis of NASH
  • 3.5. Epidemiology
  • 3.6. Animal Models for NASH
  • 3.7. Clinical Trial Designs and End Points
  • 3.8. Regulatory Initiatives

4. TREATMENT OPTIONS AND DIAGNOSTIC SOLUTIONS

  • 4.1. Context and Background
  • 4.2. Treatment Options for NASH
    • 4.2.1. General Recommendations
    • 4.2.2. Pharmacological Interventions
    • 4.2.3. Natural Products for the Treatment of NASH
  • 4.3. Diagnostic Solutions

5. MARKET DYNAMICS

  • 5.1. Chapter Overview
  • 5.2. Key Growth Drivers
    • 5.2.1. Growing Worldwide Prevalence of Obesity and Diabetes
    • 5.2.2. Increase in Research and Development Initiatives
    • 5.2.3. Promising Late Stage Molecules
  • 5.3. Challenges
    • 5.3.1. Lack of Understanding of Pathophysiology of NASH
    • 5.3.2. Incompetent Diagnostic Tools for NASH

6. MARKET OVERVIEW

  • 6.1. Context and Background
  • 6.2. Pipeline of Drugs
  • 6.3. Pipeline Analysis
    • 6.3.1. Distribution by Phase of Development
    • 6.3.2. Distribution by Type of Molecule
    • 6.3.3. Distribution by Route of Administration

7. UPCOMING NASH DRUGS: DETAILED PROFILES

  • 7.1. Context and Background
  • 7.2. Lipaglyn, Saroglitazar (ZYH1), Zydus-Cadila
    • 7.2.1. Drug Overview
    • 7.2.2. Background
    • 7.2.3. Mechanism of Action
    • 7.2.4. Development Status
    • 7.2.5. Key Clinical Trial Results
    • 7.2.6. Patent Portfolio
  • 7.3. INT-747 (Obeticholic acid (OCA))/ DSP-1747, Intercept Pharmaceuticals
    • 7.3.1. Drug Overview
    • 7.3.2. Background
    • 7.3.3. Mechanism of Action
    • 7.3.4. Development Status
    • 7.3.5. Key Clinical Trial Results
    • 7.3.6. Manufacturing
    • 7.3.7. Patent Portfolio
    • 7.3.8. Collaborations
  • 7.4. Emricasan (IDN-6556), Conatus Pharmaceuticals
    • 7.4.1. Drug Overview
    • 7.4.2. Mechanism of Action
    • 7.4.3. Development Status
    • 7.4.4. Key Clinical Trial Results
    • 7.4.5. Manufacturing
    • 7.4.6. Collaborations
  • 7.5. GFT505, Genfit
    • 7.5.1. Drug Overview
    • 7.5.2. Background
    • 7.5.3. Mechanism of Action
    • 7.5.4. Development Status
    • 7.5.5. Key Clinical Trial Results
    • 7.5.6. Patent Portfolio
    • 7.5.7. Collaborations
  • 7.6. Cenicriviroc (CVC), Tobira Therapeutics
    • 7.6.1 Drug Overview
    • 7.6.2. Background
    • 7.6.3. Mechanism of Action
    • 7.6.4. Development Status
    • 7.6.5. Key Clinical Trial Results
    • 7.6.6. Manufacturing
    • 7.6.7. Collaborations
  • 7.7. Aramchol, Galmed Pharmaceuticals
    • 7.7.1. Drug Overview
    • 7.7.2. Background
    • 7.7.3. Mechanism of Action
    • 7.7.4. Development Status
    • 7.7.5. Key Clinical Trial Results
    • 7.7.6. Manufacturing
    • 7.7.7. Collaborations
  • 7.8. Simtuzumab (GS-6624), Gilead Sciences
    • 7.8.1. Drug Overview
    • 7.8.2. Mechanism of Action
    • 7.8.3. Development Status
    • 7.8.4. Key Clinical Trial Results
    • 7.8.5. Manufacturing
    • 7.8.6. Patent Portfolio
    • 7.8.7. Collaborations
  • 7.9. Procysbi (RP103), Raptor Pharmaceuticals
    • 7.9.1. Drug Overview
    • 7.9.2. Background
    • 7.9.3. Mechanism of Action
    • 7.9.4. Development Status
    • 7.9.5. Key Clinical Trial Results
    • 7.9.6. Manufacturing
    • 7.9.7. Patent Portfolio
    • 7.9.8. Collaborations
  • 7.10. Remogliflozinetabonate (Remo), Islet Sciences / BHV Pharma
    • 7.10.1. Drug Overview
    • 7.10.2. Background
    • 7.10.3. Mechanism of Action
    • 7.10.4. Development Status
    • 7.10.5. Key Clinical Trial Results
    • 7.10.6. Patent Portfolio
    • 7.10.7. Collaborations

8. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Important Parameters and Key Assumptions
    • 8.2.1. Target Patient Population
    • 8.2.2. Diagnosis Rate
    • 8.2.3. Drug Penetration Rate
    • 8.2.4. Price of the Drug
  • 8.3. Scenario Analysis: Description and Methodology
  • 8.4. Overall NASH Market, 2015-2025

9. COMPANY PROFILES

  • 9.1. Chapter Overview
  • 9.2. Conatus Pharmaceuticals
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. NASH Drugs Portfolio
    • 9.2.4. Partnerships
    • 9.2.5. Future Outlook
  • 9.3. Galmed Pharmaceuticals
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. NASH Drugs Portfolio
    • 9.3.4. Partnerships
    • 9.3.5. Future Outlook
  • 9.5. Genfit
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. NASH Drugs Portfolio
    • 9.5.4. Partnerships
    • 9.5.5. Future Outlook
  • 9.6. Gilead Sciences
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. NASH Drugs Portfolio
    • 9.6.4. Partnerships
    • 9.6.5. Future Outlook
  • 9.7. Intercept Pharmaceuticals
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. NASH Drugs Portfolio
    • 9.7.4. Partnerships
    • 9.7.5. Future Outlook
  • 9.8. Novo Nordisk
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. NASH Drugs Portfolio
    • 9.8.4. Future Outlook
  • 9.9. Raptor Pharmaceuticals
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. NASH Drugs Portfolio
    • 9.9.4. Partnerships
    • 9.9.5. Future Outlook
  • 9.10. Zydus Cadila
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. NASH Drugs Portfolio

10. CONCLUSION

  • 10.1. NASH: Emerging As the Next Epidemic
  • 10.2. Lifestyle Interventions: A Solution To Reduce Severity of the Disease
  • 10.3. Diagnosis of Nash Remains a Challenge
  • 10.4. With a High Unmet Need; Nash is Anticipated To Be a Multi-Billion Market

11. INTERVIEW TRANSCRIPTS

  • 11.1. Chapter Overview
  • 11.2. BiOrion Technologies (Herman Steen, CEO)
  • 11.3. Phenex Pharmaceuticals (Dr. Claus Kremoser, CEO)
  • 11.4. Tobira Therapeutics (Laurent Fischer, CEO and Andrew McKibben, Director, Finance & Corporate Development)
  • 11.5. Verlyx Pharma (Dr. Pierre Falardeau, CEO)
  • 11.6. Connexios (ShobhaVijayaraghavan, VP Business Development)

12. APPENDIX1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Spectrum of Non Alcoholic Fatty Liver Disease
  • Figure 3.2: NAFLD: Classification
  • Figure 3.3: Chronology of the Pace of Research and Development for NASH
  • Figure 3.4: NAFLD and NASH: Pathogenesis
  • Figure 3.5: Prevalence of NASH
  • Figure 3.6: Prevalence of NASH in the US
  • Figure 3.7: Design and End-points for Clinical Trials of NASH
  • Figure 5.1: NASH Drugs Market: Key Market Drivers and Restraints
  • Figure 5.2: Rise in Overweight and Obesity Rate, 1980-2013
  • Figure 5.3: Diabetes: Worldwide Prevalence and Diagnosis (Million)
  • Figure 5.4: Diabetes: Prevalence by Regions /Countries (2014), Million
  • Figure 5.5: Diabetes: Diagnosed Cases by Regions /Countries (2014), Million
  • Figure 6.1: NASH Drugs: Distribution by Phase of Development
  • Figure 6.2: NASH Drugs: Distribution by Type of Molecule
  • Figure 6.3: NASH Drugs: Distribution by Route of Administration
  • Figure 7.1: Lipaglyn (Saroglitazar): Development Timeline
  • Figure 7.2: INT-747: Mechanism of Action
  • Figure 7.3: INT-747: Design of Phase III REGENERATE Trial
  • Figure 7.4: GFT505: Mechanism of Action
  • Figure 8.1: NASH Future Market Scenarios
  • Figure 8.2: Overall NASH Drugs Market, 2018- 2025 (USD Million)
  • Figure 8.3: NASH Drugs Market: Distribution by Region, 2025 (USD Million)
  • Figure 8.4: Timeline: Launch of NASH Molecules
  • Figure 8.5: NASH Drugs Market: Indicative Distribution by Drugs: 2020, 2025
  • Figure 8.6: Market Scenarios, Comparative Positioning (USD Billion)
  • Figure 9.1: Conatus Pharmaceuticals: NASH Drugs Pipeline
  • Figure 9.2: Galmed Pharmaceuticals: NASH Drugs Pipeline
  • Figure 9.3: Genfit: Development History
  • Figure 9.4: Genfit: Revenues, 2010-2014 (EUR Million)
  • Figure 9.5: Genfit: Distribution of Revenues, 2014 (EUR Million)
  • Figure 9.6: Genfit: NASH Drugs Pipeline
  • Figure 9.7: Gilead Sciences: Net Revenues, 2010 - H1 2015 (USD Billion)
  • Figure 9.8: Gilead Sciences: Distribution of Revenues, 2014 (USD Million)
  • Figure 9.9: Gilead Sciences: NASH Drugs Pipeline
  • Figure 9.10: Intercept Pharmaceuticals: Revenues, 2011- H1 2015 (USD Million)
  • Figure 9.11: Intercept Pharmaceuticals: NASH Drugs Pipeline
  • Figure 9.12: Novo Nordisk Revenues, 2010 - H1 2015 (DKK Million)
  • Figure 9.13: Novo Nordisk Revenues: Distribution by Business Segment, 2014 (DKK Billion)
  • Figure 9.14: Novo Nordisk: NASH Drugs Pipeline
  • Figure 9.15: Raptor Pharmaceuticals: Revenues, 2013- H1 2015 (USD Million)
  • Figure 9.16: Raptor Pharmaceuticals: NASH Drugs Pipeline
  • Figure 9.17: Zydus Cadila: Revenues, 2010-2014 (INR Billion)
  • Figure 9.18: Zydus Cadila: Revenues by Geographies, 2014 (INR Billion)
  • Figure 9.19: Zydus Cadila: NASH Drugs Pipeline
  • Figure 10.1: NASH Drugs Market (USD Million), 2018, 2020 and 2025

List of Tables:

  • Table 3.1: Various Animal Models for the Study of NASH
  • Table 3.2: Important Definitions and Specifications for NASH Clinical Studies
  • Table 3.3: Pre-fibrotic NAFLD/ NASH: Diagnostic Categories and Associated Histologic Lesions
  • Table 4.1: Recommended Nutritional Guidelines for NAFLD/ NASH
  • Table 4.2: Plant Extracts Used for the Treatment of NASH
  • Table 4.3: Polyherbal Medications for Management of NASH
  • Table 4.4: Phytochemicals for Treatment of NASH
  • Table 4.5: NASH: Non-invasive Imaging Diagnostic Methods
  • Table 6.1: NASH: Pipeline of Drugs
  • Table 7.1: NASH: Molecules in Late Stage of Development
  • Table 7.2: Saroglitazar: Clinical Trials
  • Table 7.3: Saroglitazar: Patent Portfolio
  • Table 7.4: FLINT Trial: Key Baseline Charcateristics
  • Table 7.5: INT-747: Research and Development Expenses
  • Table 7.6: INT-747: Patent Portfolio
  • Table 7.7: Emricasan: Phase 1 Clinical Trial Summary
  • Table 7.8: Emricasan: Clinical Trial Results
  • Table 7.9: GFT505: Clinical Trials
  • Table 7.10: CVC: Clinical Trials
  • Table 7.11: CVC: Patent Portfolio
  • Table 7.12: Aramchol: Clinical Trials
  • Table 7.13: Aramchol: Important Paramters of ARREST Study
  • Table 7.14: Aramchol: Completed Clinical Trials
  • Table 7.15: Simtuzumab: Clinical Trials
  • Table 7.16: Simtuzumab: Patent Portfolio
  • Table 7.17: RP103: Clinical Trials
  • Table 7.18: RP103: Treatment Regimen
  • Table 7.19: RP103: Patent Portfolio
  • Table 7.20: Remogliflozin etabonate: Clinical Development Overview
  • Table 7.21: Remogliflozin etabonate: Patent Portfolio
  • Table 8.1: Opportunity Analysis: Target Patient Population
  • Table 8.2: Opportunity Analysis: Diagnosis Rate
  • Table 8.3: Opportunity Analysis: Drug Penetration Rates
  • Table 8.4: Opportunity Analysis: Price of the Drug
  • Table 9.1: INT-747: Planned 2015 Milestones
  • Table 12.1: Rise in Overweight and Obesity Rate, 1980-2013
  • Table 12.2: Diabetes: Worldwide Prevalence and Diagnosis (Million)
  • Table 12.3: Diabetes: Prevalence by Regions/ Countries (2014), Million
  • Table 12.4: Diabetes: Diagnosed Cases by Regions/ Countries (2014), Million
  • Table 12.5: NASH Drugs: Distribution by Phase of Development
  • Table 12.6: NASH Drugs: Distribution by Type of Molecule
  • Table 12.7: NASH Drugs: Distribution by Route of Administration
  • Table 12.8: Overall NASH Drugs Market, 2018-2025 (USD Million)
  • Table 12.9: NASH Drugs Market: Indicative Distribution by Drugs: 2020, 2025
  • Table 12.10: Market Scenarios, Comparative Positioning (USD Billion)
  • Table 12.11: Genfit: Revenues, 2010-2014 (EUR Million)
  • Table 12.12: Genfit: Distribution of Revenues, 2014 (EUR Billion)
  • Table 12.13: Gilead Sciences: Net Revenues, 2010 - H1 2015 (USD Billion)
  • Table 12.14: Gilead Sciences: Distribution of Revenues, 2014 (USD Million)
  • Table 12.15: Intercept Pharmaceuticals: Revenues, 2011- H1 2015 (USD Million)
  • Table 12.16: Novo Nordisk Revenues, 2010 - H1 2015 (DKK Million)
  • Table 12.17: Novo Nordisk Revenues: Distribution by Business Segment, 2014 (DKK Billion)
  • Table 12.18: Raptor Pharmaceuticals: Revenues, 2013-H1 2015 (USD Million)
  • Table 12.19: Zydus Cadila: Revenues, 2010-2014 (INR Billion)
  • Table 12.20: Zydus Cadila: Revenues by Geographies, 2014 (INR Billion)
  • Table 12.21: Nash Drugs Market (USD Million), 2018, 2020, and 2015

Listed Companies:

The following companies and organizations have been mentioned in this report

  • 1. Alnylam Pharmaceuticals
  • 2. American Diabetes Association
  • 3. Arresto Biosciences
  • 4. AstraZeneca
  • 5. BiOrion Technologies
  • 6. BHV Pharma
  • 7. Boehringer Ingelheim
  • 8. Bristol-Myers Squibb
  • 9. Cadila Healthcare
  • 10. Cerenis Therapeutics
  • 11. Conatus Pharmaceuticals
  • 12. Connexios
  • 13. DS Biopharma
  • 14. Durect
  • 15. Encode Pharmaceuticals
  • 16. Enanta Pharmaceuticals
  • 17. Endonovo Therapeutics
  • 18. Exalenz Bioscience
  • 19. Fournier
  • 20. Galectin Therapeutics
  • 21. Galmed Pharmaceuticals
  • 22. Genfit
  • 23. Gilead Sciences
  • 24. Idun
  • 25. Immune Pharmaceuticals
  • 26. ImmuNess
  • 27. Immuron Ltd.
  • 28. Intercept Pharmaceuticals
  • 29. Isis Pharmaceuticals
  • 30. Islet Sciences
  • 31. Johns Hopkins University
  • 32. Kadmon
  • 33. Kissei Pharmaceuticals
  • 34. KrisaniBio
  • 35. Kyorin Pharmaceutical
  • 36. LibbsFarmaceutica
  • 37. Ligand
  • 38. Madrigal Pharmaceuticals
  • 39. Matinas BioPharma
  • 40. McGill University
  • 41. Medicinova
  • 42. Merck
  • 43. Metabolic Solutions
  • 44. Mochida Pharmaceutical Company
  • 45. Naia Pharmaceuticals
  • 46. National Institute of Diabetes and Digestive and Kidney Diseases
  • 47. NAFLD Clinical Research Network
  • 48. Niigata University
  • 49. NGM Biopharmaceuticals
  • 50. Nimbus Therapeutics
  • 51. Novo Nordisk
  • 52. One Way Liver Genomics SL
  • 53. Perrigo API
  • 54. Pfizer
  • 55. Pierre Fabre
  • 56. Phenex Pharmaceuticals
  • 57. Raptor Pharmaceuticals
  • 58. Regulus Therapeutics
  • 59. Sanofi-Aventis
  • 60. SATT Sud Est
  • 61. Seattle Children's Research Institute
  • 62. Servier
  • 63. Shire
  • 64. Sumitomo Dainippon Pharma
  • 65. Taiwan Pharmaceuticals
  • 66. Therapix Biosciences
  • 67. Tobira Therapeutics
  • 68. University of Arizona
  • 69. University of California
  • 70. University of Perugia
  • 71. Verlyx Pharma
  • 72. Verva Pharmaceuticals
  • 73. Viking Therapeutics
  • 74. ViroBay
  • 75. XTuit Pharmaceuticals
  • 76. Zafgen
  • 77. Zydus Cadila
Back to Top